Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
6 Sep 24
8-K
Entry into a Material Definitive Agreement
2 Aug 24
8-K
Entry into a Material Definitive Agreement
8 Jul 24
8-K
Regulation FD Disclosure
29 May 24
8-K
Entry into a Material Definitive Agreement
16 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Feb 24
8-K
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
22 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Dec 23
10-Q
2023 Q3
Quarterly report
17 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
8-K
RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services
12 Oct 23
8-K
Settlement and Exchange Agreement
2 Oct 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
8-K
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company
9 Aug 23
8-K
Template of Form of Phantom Stock Award Agreement
13 Jun 23
8-K
Entry into a Material Definitive Agreement
24 May 23
10-Q
2023 Q1
Quarterly report
22 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
8-K
Regulation FD Disclosure
5 May 23
10-K
2022 FY
Annual report
17 Apr 23
8-K
Entry into a Material Definitive Agreement
13 Apr 23
8-K
Form of Securities Purchase Agreement
6 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
8-K
RespireRx Pharmaceuticals Inc. Announces the Appointment Joseph Siegelbaum as an Independent Member of the Board of Directors
28 Mar 23
8-K
ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd
1 Mar 23
8-K
Regulation FD Disclosure
1 Feb 23
8-K
RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois
23 Jan 23
8-K
RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform
12 Jan 23
10-Q
2022 Q3
Quarterly report
17 Nov 22
8-K
Regulation FD Disclosure
17 Nov 22
NT 10-Q
Notice of late quarterly filing
14 Nov 22
8-K
RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4
10 Nov 22
8-K
RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery Summit
7 Nov 22
8-K
Regulation FD Disclosure
13 Sep 22
10-Q
2022 Q2
Quarterly report
22 Aug 22
NT 10-Q
Notice of late quarterly filing
15 Aug 22
8-K
Payment Settlement Agreement and Release
3 Aug 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Jun 22
Latest ownership filings
SC 13G
SAFRANEK JOHN
22 Mar 21
4
David Dickason
6 Oct 20
3
David Dickason
6 Oct 20
4
Timothy L. Jones
2 Oct 20
4
Katie MacFarlane
2 Oct 20
4
Arnold Lippa
2 Oct 20
4
Jeff Eliot Margolis
2 Oct 20
4
Katie MacFarlane
4 Aug 20
4
Richard David Jr. Purcell
4 Aug 20
4
Timothy L. Jones
4 Aug 20
3
Timothy L. Jones
4 Aug 20
4
Arnold Lippa
15 Jul 20
4
Jeff Eliot Margolis
15 Jul 20
4
Jeff Eliot Margolis
24 Mar 20
4
Arnold Lippa
24 Mar 20
4
Arnold Lippa
14 Sep 18
4
Richard David Jr. Purcell
12 Dec 17
4
JAMES S J MANUSO
12 Dec 17
4
Katie MacFarlane
12 Dec 17
4
JAMES SAPIRSTEIN
12 Dec 17
4
Arnold Lippa
12 Dec 17
4
Jeff Eliot Margolis
12 Dec 17
4
Jeff Eliot Margolis
28 Jul 17
4
Richard David Jr. Purcell
6 Jul 17
4
Jeff Eliot Margolis
5 Jul 17
4
Arnold Lippa
5 Jul 17
4
Katie MacFarlane
5 Jul 17
4
JAMES S J MANUSO
5 Jul 17
4
JAMES SAPIRSTEIN
5 Jul 17
4
Jeff Eliot Margolis
20 Jan 17
4
Katie MacFarlane
20 Jan 17
4
Arnold Lippa
20 Jan 17
4
ROBERT N WEINGARTEN
20 Jan 17
4
JAMES S J MANUSO
20 Jan 17
4
Richard David Jr. Purcell
20 Jan 17
4
JAMES SAPIRSTEIN
20 Jan 17
4
Jeff Eliot Margolis
19 Jul 16
4
Arnold Lippa
20 Jun 16
4
Jeff Eliot Margolis
20 Jun 16
4
JAMES S J MANUSO
11 Apr 16